- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Pulmonary Arterial Hypertension (PAH) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Pulmonary Arterial Hypertension (PAH) Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Pulmonary Arterial Hypertension (PAH) Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Inhalation segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs include Pfizer, Glaxosmithkline, Novartis, United Therapeutics, and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Pulmonary Arterial Hypertension (PAH) Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Inhalation
Injectables
Oral Administration
Market segment by Application can be divided into
Hospitals
Clinics
Other
The key market players for global Pulmonary Arterial Hypertension (PAH) Drugs market are listed below:
Pfizer
Glaxosmithkline
Novartis
United Therapeutics
AstraZeneca
Merck
Bayer Healthcare
Actelion Pharmaceuticals
Daiichi Sankyo
Northern Therapeutics
Aires Pharmaceuticals
Arena Pharmaceuticals
Berlin Cures
Eiger BioPharmaceuticals
Reata Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pulmonary Arterial Hypertension (PAH) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs, with price, sales, revenue and global market share of Pulmonary Arterial Hypertension (PAH) Drugs from 2019 to 2022.
Chapter 3, the Pulmonary Arterial Hypertension (PAH) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pulmonary Arterial Hypertension (PAH) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Pulmonary Arterial Hypertension (PAH) Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pulmonary Arterial Hypertension (PAH) Drugs.
Chapter 13, 14, and 15, to describe Pulmonary Arterial Hypertension (PAH) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Pulmonary Arterial Hypertension (PAH) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Inhalation
1.2.3 Injectables
1.2.4 Oral Administration
1.3 Market Analysis by Application
1.3.1 Overview: Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size & Forecast
1.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume (2017-2028)
1.4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price (2017-2028)
1.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity Analysis
1.5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Total Production Capacity (2017-2028)
1.5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers
1.6.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
1.6.3 Pulmonary Arterial Hypertension (PAH) Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Glaxosmithkline
2.2.1 Glaxosmithkline Details
2.2.2 Glaxosmithkline Major Business
2.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 United Therapeutics
2.4.1 United Therapeutics Details
2.4.2 United Therapeutics Major Business
2.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Bayer Healthcare
2.7.1 Bayer Healthcare Details
2.7.2 Bayer Healthcare Major Business
2.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Actelion Pharmaceuticals
2.8.1 Actelion Pharmaceuticals Details
2.8.2 Actelion Pharmaceuticals Major Business
2.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Daiichi Sankyo
2.9.1 Daiichi Sankyo Details
2.9.2 Daiichi Sankyo Major Business
2.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Northern Therapeutics
2.10.1 Northern Therapeutics Details
2.10.2 Northern Therapeutics Major Business
2.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Aires Pharmaceuticals
2.11.1 Aires Pharmaceuticals Details
2.11.2 Aires Pharmaceuticals Major Business
2.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.11.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Arena Pharmaceuticals
2.12.1 Arena Pharmaceuticals Details
2.12.2 Arena Pharmaceuticals Major Business
2.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.12.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Berlin Cures
2.13.1 Berlin Cures Details
2.13.2 Berlin Cures Major Business
2.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.13.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Eiger BioPharmaceuticals
2.14.1 Eiger BioPharmaceuticals Details
2.14.2 Eiger BioPharmaceuticals Major Business
2.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.14.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Reata Pharmaceuticals
2.15.1 Reata Pharmaceuticals Details
2.15.2 Reata Pharmaceuticals Major Business
2.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
2.15.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Pulmonary Arterial Hypertension (PAH) Drugs Breakdown Data by Manufacturer
3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Pulmonary Arterial Hypertension (PAH) Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturer Market Share in 2021
3.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Pulmonary Arterial Hypertension (PAH) Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region
4.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2017-2028)
4.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028)
4.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028)
4.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028)
4.5 South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028)
4.6 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Type (2017-2028)
5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2028)
5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Application (2017-2028)
6.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2028)
6.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028)
7.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028)
7.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
7.3.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028)
8.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028)
8.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
8.3.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region
9.3.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028)
10.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028)
10.3 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
10.3.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
11.3.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Pulmonary Arterial Hypertension (PAH) Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Pulmonary Arterial Hypertension (PAH) Drugs
12.3 Pulmonary Arterial Hypertension (PAH) Drugs Production Process
12.4 Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Pulmonary Arterial Hypertension (PAH) Drugs Typical Distributors
13.3 Pulmonary Arterial Hypertension (PAH) Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 6. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Glaxosmithkline Basic Information, Manufacturing Base and Competitors
Table 8. Glaxosmithkline Major Business
Table 9. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 10. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Novartis Basic Information, Manufacturing Base and Competitors
Table 12. Novartis Major Business
Table 13. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 14. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. United Therapeutics Basic Information, Manufacturing Base and Competitors
Table 16. United Therapeutics Major Business
Table 17. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 18. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 20. AstraZeneca Major Business
Table 21. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 22. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Merck Basic Information, Manufacturing Base and Competitors
Table 24. Merck Major Business
Table 25. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 26. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Bayer Healthcare Basic Information, Manufacturing Base and Competitors
Table 28. Bayer Healthcare Major Business
Table 29. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 30. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Actelion Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Actelion Pharmaceuticals Major Business
Table 33. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 34. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 36. Daiichi Sankyo Major Business
Table 37. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 38. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Northern Therapeutics Basic Information, Manufacturing Base and Competitors
Table 40. Northern Therapeutics Major Business
Table 41. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 42. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Aires Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Aires Pharmaceuticals Major Business
Table 45. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 46. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Arena Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 48. Arena Pharmaceuticals Major Business
Table 49. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 50. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Berlin Cures Basic Information, Manufacturing Base and Competitors
Table 52. Berlin Cures Major Business
Table 53. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 54. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Eiger BioPharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 56. Eiger BioPharmaceuticals Major Business
Table 57. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 58. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Reata Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 60. Reata Pharmaceuticals Major Business
Table 61. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Services
Table 62. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 63. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)
Table 64. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 65. Market Position of Manufacturers in Pulmonary Arterial Hypertension (PAH) Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 66. Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 67. Head Office and Pulmonary Arterial Hypertension (PAH) Drugs Production Site of Key Manufacturer
Table 68. Pulmonary Arterial Hypertension (PAH) Drugs New Entrant and Capacity Expansion Plans
Table 69. Pulmonary Arterial Hypertension (PAH) Drugs Mergers & Acquisitions in the Past Five Years
Table 70. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2017-2022) & (K Pcs)
Table 71. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2023-2028) & (K Pcs)
Table 72. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2017-2022) & (USD Million)
Table 73. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2023-2028) & (USD Million)
Table 74. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 75. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 76. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 77. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 78. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2017-2022) & (USD/Pcs)
Table 79. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2023-2028) & (USD/Pcs)
Table 80. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 81. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 82. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 83. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 84. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2017-2022) & (USD/Pcs)
Table 85. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2023-2028) & (USD/Pcs)
Table 86. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 87. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 88. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 89. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 90. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 91. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 92. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 93. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 94. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 95. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 96. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 97. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 98. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 99. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 100. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 101. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 102. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2017-2022) & (K Pcs)
Table 103. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2023-2028) & (K Pcs)
Table 104. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2017-2022) & (USD Million)
Table 105. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2023-2028) & (USD Million)
Table 106. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 107. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 108. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 109. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 110. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2022) & (K Pcs)
Table 111. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2023-2028) & (K Pcs)
Table 112. South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 113. South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 114. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 115. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 116. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 117. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 118. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2017-2022) & (K Pcs)
Table 119. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2023-2028) & (K Pcs)
Table 120. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2017-2022) & (USD Million)
Table 121. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2023-2028) & (USD Million)
Table 122. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs)
Table 123. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs)
Table 124. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs)
Table 125. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs)
Table 126. Pulmonary Arterial Hypertension (PAH) Drugs Raw Material
Table 127. Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials
Table 128. Direct Channel Pros & Cons
Table 129. Indirect Channel Pros & Cons
Table 130. Pulmonary Arterial Hypertension (PAH) Drugs Typical Distributors
Table 131. Pulmonary Arterial Hypertension (PAH) Drugs Typical Customers
List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Picture
Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type in 2021
Figure 3. Inhalation
Figure 4. Injectables
Figure 5. Oral Administration
Figure 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application in 2021
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Other
Figure 10. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (USD Million) & (K Pcs): 2017 & 2021 & 2028
Figure 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (2017-2028) & (K Pcs)
Figure 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Price (2017-2028) & (USD/Pcs)
Figure 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity (2017-2028) & (K Pcs)
Figure 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers
Figure 17. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints
Figure 18. Pulmonary Arterial Hypertension (PAH) Drugs Market Trends
Figure 19. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturer in 2021
Figure 20. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Manufacturer in 2021
Figure 21. Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2017-2028)
Figure 25. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2017-2028)
Figure 26. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (USD Million)
Figure 27. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (USD Million)
Figure 29. South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028)
Figure 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2017-2028)
Figure 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2017-2028) & (USD/Pcs)
Figure 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028)
Figure 35. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2017-2028)
Figure 36. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2017-2028) & (USD/Pcs)
Figure 37. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028)
Figure 38. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028)
Figure 39. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2017-2028)
Figure 40. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2017-2028)
Figure 41. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028)
Figure 45. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028)
Figure 46. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2017-2028)
Figure 47. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2017-2028)
Figure 48. Germany Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2017-2028)
Figure 57. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028)
Figure 64. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028)
Figure 65. South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2017-2028)
Figure 66. South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Pulmonary Arterial Hypertension (PAH) Drugs in 2021
Figure 78. Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs
Figure 79. Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
